Supplementary Information for

TCR-mimic bispecific antibodies to target the HIV-1 reservoir

Srona Sengupta1,2 †, Nathan Board1, ‡, Fengting Wu1, †, Milica Moskovljivic1, ‡, Jacqueline Douglass3,4,‡, Josephine Zhang1, Bruce R. Reinhold5-7, Jonathan Duke-Cohan5-7, Jeanna Yu1, Madison C. Reed1, Yasmine Tabdili1, Aitana Azurmendi8, Emily J. Fray1, Hao Zhang9, Emily Han-Chung Hsiue3,4, Katharine Jenike1, Ya-chi Ho10, Sandra B. Gabelli8, Kenneth W. Kinzler3,4,11, Bert Vogelstein3,4,11,12, Shibin Zhou3,4,11, Janet D. Siliciano1, Scheherazade Sadegh-Nasser12, Ellis L. Reinherz5-7, and Robert F. Siliciano1,12,*.

‡ These authors contributed equally.

*Corresponding author.

Contributed by Robert F. Siliciano

To whom correspondence should be addressed:

Email: rsiliciano@jhmi.edu (R.F.S.)

This PDF file includes:

Methods for phage screening
Supplementary Figures 1-9
Tables S1 to S3
SI References
Phage panning and characterization

Phage panning was performed as previously described (1). Briefly, panning consisted of four rounds of negative and positive selection. Negative selection was performed against naked streptavidin beads, free streptavidin, and irrelevant, and biotinylated A2-pMHC pre-conjugated to streptavidin beads. Negative selection was also performed against A2-bearing cells (T2s, RPMI-6666s). Positive selection was performed for each round of panning with decreasing amounts of the relevant biotinylated monomer conjugated to streptavidin beads. After each round of panning, phage were eluted with glycine (pH 2), neutralized with Tris-HCL (pH 9), amplified in SS320 cells (Lucigen), and concentrated in PEG-NaCl. Phage eluted from the 4th round of panning were diluted such that infection of bacteria produced single colonies. Individual bacterial colonies were inoculated in deep 96-well plates to produce monoclonal phage. Monoclonal phage supernatants were tested for their ability to bind to the target versus irrelevant pMHC using ELISA and flow cytometry. Phage supernatants were added to streptavidin ELISA plates pre-coated with biotinylated A2-monomers of the relevant or irrelevant pMHC, and phage binding was assessed using a rabbit anti-M13 antibody (Pierce) and a secondary conjugated to HRP. To assess phage binding to pMHC on the surface of cells, T2 cells were pulsed with 50 ug/ml peptide and 10 ug/ml B2M for 4 hrs to overnight at 37°C in RPMI 1640 + Glutamax with 1% Pen/Strep. Pulsed cells were washed once with PBS, incubated with monoclonal phage, and then stained with rabbit anti-M13 (Pierce) followed by a PE-conjugated donkey anti-rabbit secondary (Biolegend). Phage-stained cells were acquired on the Intellicyt flow cytometer and analyzed with FlowJo.

scDb Expression and Purification

Monoclonal phages that stained specifically for a particular peptide-pulsed target were sequenced to identify the expressed Fab. Gene blocks expressing this Fab fragment, the UCHT1 Fab fragment against CD3, and C’terminal His tag were cloned via Gibson assembly into the pcDNA3.4 vector backbone. scDb constructs were sequenced, amplified, and expressed via transfection into 293T cells. scDbs were purified using nickel columns (Capturem His-tag miniprep columns) using 400 mM imidazole and were desalted to remove imidazole using Zeba Spin columns. scDbs were run on SDS-PAGE and quantified using iBright densitometric analysis in comparison to a BSA standard. Large-scale preparations of scDbs were produced by ThermoFisher.
Fig. S1: Poisson LC-DIAMS detection of HLA-A*02:01-bound ALT and VLA peptides from 2.5x10^6 GFP^+ CD4^+ T cells. A, B) Detection of ALTEVVPLT (ALT) and VLAEMSQV (VLA) HIV-1 peptides in GFP^+ cells, indicated by the presence of coeluting peaks in the precursor XIC (top black trace) and the Poisson chromatogram (bottom, inverted blue trace). The elution position of the coincident peaks must also be consistent with the elution mapping as determined by an LC-DIAMS run of the synthetic set containing a set of mapping peptides shared in both the synthetic and sample runs (see Methods). Of the 64 HIV-1 HLA-A*02:01-binding peptides assayed, these two were the only ones detected in the +2-charge state. None of the 64 were detected in GFP^− cells.
Figure S2

A. Scan cycle 767
100 attomoles
AL\textsuperscript{3}TEVVPLT
m/z 475.287

Time (scan cycle units)

B. AL\textsuperscript{3}TEVVPLT
m/z 471.779 MS scan 767
AL\textsuperscript{3}TEVVPLT
m/z 475.287

m/z

C. Scan cycle 579
100 attomoles
VL\textsuperscript{3}AEAMSQV
m/z 477.755

Time (scan cycle units)

D. VL\textsuperscript{3}AEAMSQV
m/z 477.755
VL\textsuperscript{3}AEAMSQV
m/z 474.247

m/z
Fig. S2: Quantitation of HLA-A*02:01-bound peptides ALT and VLA detected from 2.5e6 GFP+ CD4+T cell by targeted LC-MS/MS. 100 attomoles of isotope-labeled heavy ALT and VLA peptides were added. A) Poisson detection plot shows heavy ALT, hence light ALT, eluting at scan 767. B) The mass spectrum at scan 767 shows precursor ion amplitudes for both light (30,000) and heavy (13,300) forms. 30000/13300 * 100 = 226 attomoles. Over 2.5 million cells this is a copy number of 54 per cell. C, D) As above with 2500/5850*100 = 43 attomoles or 10 copies/cell.
Fig. S3: Quantitation of HLA-A*02:01-bound ILK detected from 2.5e6 GFP+ CD4+ cell by targeted LC-MS/MS. 200 attomoles of isotope-labeled heavy ILK were added. A) Poisson detection plot shows
heavy ILK, hence light ILK, eluting at scan 241. B) The mass spectrum at scan 241 shows the precursor ion amplitude of the heavy form but to see the light form light form requires an expanded scale (C). That this minor peak is light ILK is shown by its Poisson signature in Fig. 1. The base isotope peak at 331.203 is overlapping with background ions, hence the first isotope peaks (marked with asterisks) is used for quantitation. $570/22400 \times 200 = 5$ attomoles which is less than 1 copy/cell.
Fig. S4: Selection of scFv specific for ALT, ILK, and VLA pMHC. A) Monoclonal phage were amplified in bacteria in a 96-well plate format after 4 rounds of selection and then incubated in streptavidin ELISA plates coated with biotinylated ALT pHLA-A2, ILK pHLA-A2, VLA pHLA-A2, or an isotype pHLA-A2 control. Plates were washed and phage were detected by absorbance at 450 nm using rabbit anti-M13 and an HRP-conjugated mouse anti-rabbit secondary antibody. Arrows indicate phage whose scFv sequences were utilized to construct the HA29, HI12, HV114, and HV115 scDbs described in the manuscript. Well H12 was not inoculated with phage and therefore served as a no phage control.
Fig. S5: Flow cytometry characterization of specific monoclonal phage. pMHC-specific monoclonal phage clones that bound >2 fold higher to the target vs irrelevant pMHC-A2 in monoclonal ELISAs were tested for binding on T2 (HLA-A*02:01+) cells pulsed with 50 ug/ml of the indicated peptide. Phage binding was assessed by flow cytometry using a rabbit anti-M13 primary antibody and a donkey anti-Rabbit secondary antibody conjugated to phycoerythrin (PE). Phage binding was quantified by PE
median fluorescence intensity (MFI), and the ratio of monoclonal phage bound to cells pulsed with the
cognate or irrelevant peptides plus beta-2 microglobulin (B2M) was used to rank pMHC-specific phage by
specificity. A-C) The MFI ratio of HA, HI, or HV-specific phage binding to cognate (ALT, ILK, or VLA
peptides, respectively) versus irrelevant peptide-pulsed cells is plotted. D) Peptide stabilization of cell-
surface HLA-A2 on T2 cells is shown with all three candidate target peptides. E) Representative
histograms of HA29 phage clone binding to T2 cells pulsed with 10 ug/ml B2M only (gray) or B2M + 50
ug/ml ALT (green), ILK (orange), or VLA peptides. A large shift in phage binding with ALT-pulsed cells is
observed. F) Monoclonal phage clone HI12 shows increased binding to T2 cells pulsed with the cognate
peptide (ILK) versus irrelevant peptides (VLA and ALT). G) Additional monoclonal phage screening via
flow cytometry for VLA-specific phage yielding specific clones HV115 and HV154 are shown.
Fig. S6: Selection of HA29 and HI12-scDbs for further characterization. A) T2 cells were pulsed with 1 μg/ml ALT or ILK peptides and 10 μg/ml B2M and co-cultured with pre-activated CD8+ T cells at a 1:1 E to T ratio. HA or HI-specific scDbs were added at the indicated concentrations. After 72 hrs, supernatants from co-cultures were snap frozen and assayed for secreted MIP1β. B) T2 cells were pulsed with the ALT
or ILK peptides at the indicated concentrations and 10 ug/ml B2M. Pulsed T2 cells were incubated with pre-activated CD8\(^+\)T cells (1:2 E to T) and with 0.25 nM of HA29, HA122, and HI155-scDbs and .5 nM of HI12-scDb for 72 hrs. Co-culture supernatants were harvested and assayed for MIP1\(\beta\). C) T2 cells were pulsed with indicated concentrations of the VLA peptide and co-cultured with pre-activated CD8\(^+\)T cells in the presence of 25 ng/ml HV115. CTL activation in response to decreasing doses of peptide was measuring using surface CD69\(^+\) levels.
Figure S7: Characterization of HA29-scDb binding. We generated a library of 171 positional scanning variant peptides by substituting each residue of the original peptide with the 19 other possible amino acids as previously described (1, 2). T2 cells were then pulsed with each variant at 10 uM and co-cultured with pre-activated CD8\(^+\)T cells from healthy donors. A) Supernatants were assayed for MIP1\(\beta\) at 24 hours, and the mean of three technical replicates is plotted as a heatmap. Black boxes indicate the amino acids in the parental peptides. B) To assess for differential peptide affinity for A2 and peptide-induced A2 upregulation on T2 cells post-pulsing, we also stained for surface HLA-A2 levels.
**Fig. S8: HA29 and HI12-scDb induce polyfunctional CD8^+T cell responses.** T2 cells were pulsed with the ALT or ILK peptides at the indicated concentrations. 10 X 10^4 peptide-pulsed cells were co-cultured with 5 X 10^4 pre-activated CD8^+T cells (1:2 E to T) in the presence of .25 nM HA29 or HI12 scDb for 72 hrs. Supernatants from co-cultures were assayed for the indicated effector molecules using.
Legendplex. Specific activation of CD8+T cells by HA29 and HI12 was observed in response to cells pulsed with the cognate but not irrelevant pMHC at doses down to the nanomolar range.
Fig. S9: HA29-scDbbs induce viral suppression even in infected cells with A2 downregulation. A) Suppression assays were set up using target cells (activated CD4+ T cells from an A2-expressing healthy donor) infected with ΔEnv NL4.3 EGFP and co-cultured with autologous pre-stimulated CD8+ T cells for 72 hrs (see Methods) in the presence of HA29 or H2-scDb. A) MFI of surface HLA-A2 (BB7.2 clone) levels are shown from GFP+ or GFP- cells from two biological replicates of infected cells used in suppression
assays. B) Representative flow cytometry plots of residual viable A2+ GFP+ cells after 3 days of co-culture in a suppression assay, showing a dose-dependent decrease with the HA29-scDb but no decrease with the H2-scDb. C) Healthy donor HLA-A*02:01+ CD4+T cells were activated with CD3/CD28 Dynabeads for 72 hrs and infected with ΔEnv NL4.3 EGFP. Two days post infection, infected or uninfected CD4+T cells were co-cultured at a 1:3 E:T ratio with autologous human CD8+T cells (15 X10⁴ targets and 5 X10⁴ CD8+T cells) with the HA29-scDb at 25 ng/ml for 72 hr. scDb-induced CD8+T cell activation was measured by MIP1β ELISAs from co-culture supernatants. D) %Viable cells as determined by flow cytometry in uninfected co-cultures to assess for background killing by increasing doses of HA29-scDb. Data in C show mean ± SD analyzed by two-way ANOVA followed by Tukey’s Multiple Comparison Test. Data in D represent the mean ± SD of three independent experiments analyzed by one-way ANOVA followed by Dunnett’s multiple comparison test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
Table S1: Predicted HLA-A*02:01 binding peptides from the HIV-1 proteome (excluding Env) for analysis by LC-DIAMS

| Sequence* | Protein | Amino Acid Position† |
|-----------|---------|----------------------|
| ILGQLQPSL | Gag | 60 → 68 |
| SLQTGSEEL | Gag | 67 → 75 |
| RSLYNTIAVL | Gag | 76 → 85 |
| SLYNTIAVL | Gag | 77 → 85 |
| YNTIAVLYCV | Gag | 79 → 88 |
| NTIAVLYCV | Gag | 80 → 88 |
| VLYCVHQRI | Gag | 84 → 92 |
| SQVSQNYPI | Gag | 126 → 134 |
| TLNAWVKVV | Gag | 151 → 159 |
| QDLNMTLNTV | Gag | 182 → 191 |
| AAEWDRLHPV | Gag | 209 → 218 |
| MTHNPPITV | Gag | 250 → 258 |
| ILGLNKIVRM | Gag | 267 → 276 |
| RMYSPTSIL | Gag | 275 → 283 |
| ATLEEMMTA | Gag | 341 → 349 |
| EMMTACQGV | Gag | 345 → 353 |
| RVAEAMSQVF | Gag | 361 → 370 |
| VLAEAMSQVF | Gag | 362 → 370 |
| VLAEAMSQVT | Gag | 362 → 371 |
| AMSQVTNPAT | Gag | 366 → 374 |
| FLQSRPPEP | Gag | 448 → 456 |
| FLQSRPPEPTA | Gag | 448 → 457 |
| DILDLWIYHT | Nef | 108 → 117 |
| ILDLWIYHT | Nef | 109 → 117 |
| LTFCWCYKL | Nef | 137 → 145 |
| LTFCWCYKLV | Nef | 137 → 146 |
| FGWCYKLP | Nef | 139 → 148 |
| KLVPVEPDKV | Nef | 144 → 153 |
| GMDDPERE | Nef | 172 → 180 |
| KMUGGIGGFI | Pol | 101 → 110 |
| ROYDQILIEI | Pol | 113 → 122 |
| ILIEICGHKA | Pol | 118 → 127 |
| TVLVGPTPV | Pol | 130 → 138 |
| Sequence   | Pol     | Region     |
|------------|---------|------------|
| NLLTQIGCTL | Pol     | 144 → 153  |
| TLFNPISPI  | Pol     | 152 → 160  |
| KALVEICTEM | Pol     | 187 → 196  |
| ALVEICTEM  | Pol     | 188 → 196  |
| VQLGIPHPA  | Pol     | 245 → 253  |
| YTAFTIPS   | Pol     | 282 → 290  |
| AIFQCSMTKI | Pol     | 313 → 322  |
| IYQYMDDLTV | Pol     | 335 → 344  |
| YMDDLYVGS  | Pol     | 338 → 346  |
| HLLRWGFTT  | Pol     | 363 → 371  |
| FLWMGYELHP | Pol     | 382 → 391  |
| YELHPDKWTV | Pol     | 387 → 396  |
| VLPEKDSWTV | Pol     | 400 → 409  |
| KLVGKLNWA  | Pol     | 414 → 422  |
| KLLRGTKAL  | Pol     | 436 → 444  |
| KALTEVVPL  | Pol     | 442 → 450  |
| KALTEVVPLT | Pol     | 442 → 451  |
| ALTEVVPLT  | Pol     | 443 → 451  |
| ILKEPVHG   | Pol     | 464 → 472  |
| ATWIPEWEFV | Pol     | 563 → 572  |
| YQLEKEPII  | Pol     | 582 → 590  |
| PIIGAETFYV | Pol     | 588 → 597  |
| IIGAETFYYV | Pol     | 589 → 597  |
| IIGAETFYYVD| Pol     | 589 → 598  |
| LALQDSGLEV | Pol     | 639 → 648  |
| ALQDSGLEV  | Pol     | 640 → 648  |
| IVTDSQYAL  | Pol     | 650 → 658  |
| VLFLDGIDKA | Pol     | 714 → 723  |
| RAMASDFNL  | Pol     | 735 → 743  |
| MASDFNLPPV | Pol     | 737 → 746  |
| ASDFNLPV   | Pol     | 738 → 746  |
| GQVDCSPG   | Pol     | 767 → 775  |
| HLEGKVILV  | Pol     | 782 → 790  |
| HLEGKVILV  | Pol     | 782 → 790  |
| KVILVAHVH  | Pol     | 786 → 794  |
| LLDTGADDTV  | Pol     | 79 → 88    |
| YIEAEEIPA  | Pol     | 798 → 806  |
| LLKLAGRWPV | Pol     | 816 → 825  |
| HLKTAVQMAV | Pol     | 886 → 895  |
| Peptide       | Protein | Positions   |
|--------------|---------|------------|
| KLLWKGEGEVA  | Pol     | 955 → 963  |
| KLLWKGEGAV   | Pol     | 955 → 964  |
| LLWKGEGAV    | Pol     | 956 → 964  |
| LLWKGEGAVV   | Pol     | 956 → 965  |
| KQMAGDDCV     | Pol     | 988 → 996  |
| TYLGRSAEPV    | Rev     | 62 → 71    |
| YLGRSAEPV     | Rev     | 63 → 71    |
| QILVESPTV     | Rev     | 101 → 109  |
| ILVESPTVL     | Rev     | 102 → 110  |
| WQVMIVWQV     | Vif     | 5 → 13     |
| KRLVKHHMYI    | Vif     | 22 → 31    |
| KISSEVHIPL    | Vif     | 50 → 59    |
| LVITTYWGL     | Vif     | 64 → 72    |
| SLQYLALAA     | Vif     | 144 → 152  |
| SLQYLALAAL    | Vif     | 144 → 153  |
| LQYLALAAL     | Vif     | 145 → 153  |
| KQIKPPLPSV    | Vif     | 157 → 166  |
| WTLELLEEEL    | Vpr     | 18 → 26    |
| LLEELKSEAV    | Vpr     | 22 → 31    |
| IRILQQLLFI    | Vpr     | 61 → 70    |
| RILQQLLFI     | Vpr     | 62 → 70    |
| QLFIHFRI      | Vpr     | 66 → 74    |
| PIIVAIVALV    | Vpu     | 3 → 13     |
| IIVAIVALV     | Vpu     | 5 → 13     |
| IIVAIVALVV    | Vpu     | 5 → 14     |
| AIVALVVAI     | Vpu     | 8 → 16     |
| ALVVAIIAI     | Vpu     | 11 → 20    |
| LVVAILAI      | Vpu     | 12 → 20    |
| LVVAILIAIV    | Vpu     | 12 → 21    |
| VVAIIAIV      | Vpu     | 13 → 21    |
| IIIAIVVWSI    | Vpu     | 16 → 25    |
| IIAIVVWSI     | Vpu     | 17 → 25    |
| IIAIVVWSIV    | Vpu     | 17 → 26    |
| RLIDRLIERA    | Vpu     | 41 → 50    |
| ALVEMGVEM     | Vpu     | 63 → 71    |

*No shading indicates peptides with fragmentation patterns detected by Poisson LC-DIAMS (64 peptides). Peach shading indicates peptides for which fragmentation patterns could not be identified by LC-DIAMS (43 peptides). Green shading indicates peptides that yielded fragmentation patterns by LC-DIAMS and were detected on infected (GFP+) cells (3 peptides).†Numbers represent amino acid position relative to protein start in HXB2.
Table S2: Characteristics of each pMHC-I target

| scDb Identifier | HLA Haplotype | Epitope Specificity | Epitope Location |
|-----------------|---------------|---------------------|------------------|
| HA              | A*02:01       | ALTEVVPLT           | Pol (RT)         |
| HI              | A*02:01       | ILKEPVHGV           | Pol (RT)         |
| HV              | A*02:01       | VLAEMSQV            | Gag (p24-p2)     |

Table S3: Sequences of V<sub>H</sub> and V<sub>L</sub> for relevant scDb's

| scFv  | VH  | VL  |
|-------|-----|-----|
| HV115-scDb | EVQLVESGGLVQPGGLRLSCAASGFNVTSVMHVVRQAPGKLEGLEWAMA| DIQMTQSPSSLSASVGDRTITCRASQDNTAVAVYQQKPGKAPKLLYIYASFLYS| |
|       | GFNVNTSVMHVVRQAPGKLEGLEWAMA | VNNTAVAYQKPGKAPKLLYIYASFLYS | |
|       | MFYPSDQTMNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRSMSYYSAFVYWGQTLTVSS | GYPVVPSRFSGSRSGTDFLTISLQPEDFATYECQQYYWYPITFGQGTVEIK | |
| HI12-scDb | DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAVYQQKPGKAPKLLYIYASFLYS | EVQLVESGGLVQPGGLRLSCAASSGF | |
|       | DVNTAVAWYQQKPGKAPKLLYIYASFLYS | GYPVVPSRFSGSRSGTDFLTISLQPEDFATYECQQYYWYPITFGQGTVEIK | |
|       | LYSGVPSRFSGSRSGTDFLTISLQPEDFATYECQQYYWYPITFGQGTVEIK | EVQLVESGGLVQPGGLRLSCAASSGF | |
| HA29-scDb | DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAVYQQKPGKAPKLLYIYASFLYS | EVQLVESGGLVQPGGLRLSCAASSGF | |
|       | DVNTAVAVYQQKPGKAPKLLYIYASFLYS | GYPVVPSRFSGSRSGTDFLTISLQPEDFATYECQQYYWYPITFGQGTVEIK | |
|       | LYSGVPSRFSGSRSGTDFLTISLQPEDFATYECQQYYWYPITFGQGTVEIK | EVQLVESGGLVQPGGLRLSCAASSGF | |
| H2-scDb (2) | DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAVYQQKPGKAPKLLYIYASFLYS | EVQLVESGGLVQPGGLRLSCAASSGF | |
|       | DVNTAVAVYQQKPGKAPKLLYIYASFLYS | GYPVVPSRFSGSRSGTDFLTISLQPEDFATYECQQYYWYPITFGQGTVEIK | |
|       | LYSGVPSRFSGSRSGTDFLTISLQPEDFATYECQQYYWYPITFGQGTVEIK | EVQLVESGGLVQPGGLRLSCAASSGF | |
SI References

1. J. Douglass, et al., Bispecific antibodies targeting mutant RAS neoantigens. *Sci. Immunol.* 6, eabd5515 (2021).

2. E. H. C. Hsiue, et al., Targeting a neoantigen derived from a common TP53 mutation. *Science 371* (2021).